Literature DB >> 13629433

Evaluation of thenalidine tratrate (sandostene) in dermatological disorders.

N A GETZLER, L P EREAUX.   

Abstract

Entities:  

Keywords:  ANTIHISTAMINICS/therapeutic use; SKIN DISEASES/therapy

Mesh：

Substances：

Year:  1959        PMID： 13629433      PMCID： PMC1830689     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN： 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  6 in total

1.  Alteration of wheal resorption time by intravenous use of an antihistaminic drug and a calcium salt.

Authors:  J H HARVEY; F KALZ
Journal:  Can Med Assoc J       Date:  1959-03-15       Impact factor: 8.262

2.  [Studies on the mechanism of calcium effects on small blood vessels with the aid of wheal resorption].

Authors:  H J HEITE; C P SCHRADER
Journal:  Klin Wochenschr       Date:  1957-03-15

3.  Agranulocytosis associated with thenalidine (sandostene) tartrate therapy; report of three cases.

Authors:  D A ADAMS; S PERRY
Journal:  J Am Med Assoc       Date:  1958-07-05

4.  Critical analysis of a new antihistaminic-antipruritic in allergy.

Authors:  H E GAYNES; N SHURE
Journal:  Postgrad Med       Date:  1958-01       Impact factor: 3.840

5.  [Pharmacology of ASC 16 (Sandosten-calcium-Sandoz)].

Authors:  E ROTHLIN; A CERLETTI
Journal:  Int Arch Allergy Appl Immunol       Date:  1953

6.  The action of thenaldine tartrate (sandostene) in atopic dermatitis; evaluation of a new antiallergic preparation for control of pruritus and treatment of various allergic dermatoses.

Authors:  W GARBE
Journal:  Can Med Assoc J       Date:  1958-09-01       Impact factor: 8.262
  6 in total
  1 in total

1.  Thenalidine tartrate (sandostene) as an adjuvant in courses of specific desensitization.

Authors:  F GREGOIRE; M COMEAU; L ROY
Journal:  Can Med Assoc J       Date:  1960-03-05       Impact factor: 8.262
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.